Article
Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making.
Neuro-oncology - 1 Jul 2022
Lim-Fat Mary Jane, Youssef Gilbert C, Touat Mehdi, Iorgulescu J Bryan, Whorral Sydney, Allen Marie, Rahman Rifaquat, Chukwueke Ugonma, McFaline-Figueroa J Ricardo, Nayak Lakshmi, Lee Eudocia Q, Batchelor Tracy T, Arnaout Omar, Peruzzi Pier Paolo, Chiocca E Antonio, Reardon David A, Meredith David, Santagata Sandro, Beroukhim Rameen, Bi Wenya Linda, Ligon Keith L, Wen Patrick Y
Abstract excerpt
BACKGROUND: Targeted gene NGS testing is available through many academic institutions and commercial entities and is increasingly incorporated in practice guidelines for glioblastoma (GBM). This single-center retrospective study aimed to evaluate the clinical utility of incorporating NGS results in the management of GBM patients at a clinical trials-focused academic center. METHODS: We identified 1011 consecutive...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.